

UCLA

UCLA Previously Published Works

Title

The application of human amniotic membrane in the surgical management of limbal stem cell deficiency

Permalink

<https://escholarship.org/uc/item/8dp7h4ks>

Journal

The Ocular Surface, 17(2)

ISSN

1542-0124

Authors

Le, Qihua
Deng, Sophie X

Publication Date

2019-04-01

DOI

10.1016/j.jtos.2019.01.003

Peer reviewed



Published in final edited form as:

Ocul Surf. 2019 April ; 17(2): 221–229. doi:10.1016/j.jtos.2019.01.003.

The application of human amniotic membrane in the surgical management of limbal stem cell deficiency

Qihua Le, MD, PhD^{1,2} and Sophie X. Deng, MD, PhD^{1,*}

¹Stein Eye Institute, Cornea Division, David Geffen School of Medicine, University of California, Los Angeles

²Department of Ophthalmology, Eye & ENT Hospital of Fudan University, Shanghai 200031, China

Abstract

The application of human amniotic membrane (AM) has a wide spectrum of indications in the treatment of ocular surface disorders. Transplantation of AM has been incorporated routinely as a component of ocular surface reconstruction in a variety of ocular pathologies. The application of human AM can be combined with nearly all types of limbal transplantation in treating limbal stem cell deficiency (LSCD). AM provides support and possible protection to the transplanted limbal tissues and limbal stem cells owing to its mechanical and biological properties, and these properties are thought to enhance the success rate of LSC transplantation. This paper reviews the current literatures on the applications of AM in the surgical management of LSCD and summarizes the outcome of different surgical approaches. The current literature contains mostly low-level evidences in supporting the role of AM. The efficacy of AM in LSC transplantation needs to be confirmed by randomized controlled clinical trials.

I. Introduction

Limbal stem cells (LSCs) are responsible for the regeneration of corneal epithelial cells and the maintenance of the integrity and transparency of the corneal epithelium.¹ The destruction to LSCs and/or the stem cell niche leads to dysfunction or deficiency of LSCs. Limbal stem cell deficiency (LSCD) is characterized with impaired epithelial wound healing, recurrent epithelial erosions, and scarring and opacity of corneal stroma. It is one of the causes of corneal blindness. The common etiologies of LSCD include chemical/thermal burn, contact lens wear, congenital abnormalities, iatrogenic trauma, severe microbial infection, and chronic cicatricial inflammation such as Stevens-Johnson syndrome and mucous membrane pemphigoid.²

*Corresponding author: Sophie X. Deng, MD, PhD, Stein Eye Institute, University of California, Los Angeles, 100 Stein Plaza, Los Angeles CA 90095, USA, deng@jsei.ucla.edu, Telephone: (310) 206-7202, Fax: (310) 794-7906.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The authors have no commercial or proprietary interest in any concept or product described in this article.

The treatment of LSCD is challenging because corneal transplant cannot treat LSCD and will fail after the surgery. Medical treatment has limited success. Only a few mild LSCD cases are reversible by medical treatments.³ Surgical management is usually performed in cases of moderate to severe LSCD. The surgical treatment of LSCD to restore a stable ocular surface can be divided into three groups: direct transplantation of limbal tissues, transplantation of ex vivo/in vivo expanded LSCs, and transplantation of cultivated oral mucosal epithelium. Transplantation of AM has been incorporated into the LSC transplantation in nearly all surgical approaches. AM can be used alone, or as a substrate and cell carrier of LSCs. Therefore, we performed a systematic review to investigate the application of AM in the surgical management of LSCD.

II. Search Method

We performed a systematic literature search on PubMed and Medline for the papers published before December 31, 2017. The following combined search terms were used: “limbal stem cell deficiency”, “amniotic membrane”, “surgical treatment”, “limbal transplantation”, “cultivated limbal epithelial transplantation”, “simple epithelial transplantation”, “cultivated oral mucosal epithelial transplantation”, “conjunctival limbal autograft”, “conjunctival limbal allograft” and “keratolimbal allograft”. Only human studies with 15 or more cases are included in the outcome evaluation. Literature reviews, correspondence, notes, editorials and conference abstracts were excluded in the outcome evaluation. Neither language filter nor limitation of publication time was applied during the literature search. The non-English articles were translated to English to obtain the needed information. We also reviewed the references from retrieved studies manually to identify relevant articles. The data on the preparation and preservation of AM, indications of the surgery, surgical techniques, and clinical outcomes were collected.

III. Results

A. Property and preparation of human amniotic membrane

1. Structure—Amniotic membrane, which is semi-transparent, is the innermost layer of the placenta. It is composed of three layers: a monolayer of epithelium, a thick basement membrane and the avascular stroma. The basement membrane of AM, one of the thickest membranes found in human, is similar to the basement membrane of human corneal and conjunctival epithelium in composition.⁴ The structural integrity of this layer does not alter after current cryopreservation techniques.⁵

2. Properties—Human AM has multiple functions in the reconstruction of ocular surface. Mechanically, its toughness and elasticity provides mechanical support and protection to the epithelial cells. Biologically, it could promote the adhesion and migration of limbal epithelial cells and retain their in vivo properties.^{6,7} Moreover, it has the properties of anti-fibrosis, anti-inflammation, anti-angiogenesis, and anti-bacteria.⁸ Several recent studies show that a novel matrix component termed heavy chain-hyaluronan/pentraxin 3 (HC-HA/PTX3) purified from cryopreserved AM is the active component responsible for the aforementioned AM's biological properties.^{9,10} HC-HA/PTX3 complex also uniquely maintains limbal niche cells to support the quiescence of LSCs.¹⁰ In addition, AM has low

immunogenicity because there is a lacking expression of human leukocyte antigen-A, B, or DR antigens.

3. Preparation, sterilization and preservation

a. Preparation: The method of AM preparation was first described by Tseng.¹¹ In brief, the donors of placenta are selected by serological tests to exclude hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), and syphilis. The placenta is washed by a sterile antibiotic solution, which contains 50µg/ml of penicillin, 50µg /ml of streptomycin, 100µg g/ml of neomycin, and 2.5µg /ml of amphotericin B. Then the AM is separated from the rest of the chorion by blunt dissection, and placed on the nitrocellulose filter paper (pore size: 0.45µm) with the stromal side facing down. The filter paper and the adherent AM was then cut into pieces with the approximate size of 3 cm × 4 cm. This method are used by many study centers with some minor modifications in different studies.¹²⁻¹⁵

b. Sterilization: The cryopreserved AM is usually treated with antibiotics and antimycotics as mentioned above to prevent microbial infection from contamination during processing. Alternatively, the freeze-dried or air-dried AM is usually sterilized either by 25 kGy gamma irradiation,¹⁶⁻¹⁸ or by peracetic acid/ethanol mixture.¹⁹ It is also reported that supercritical carbon dioxide can be used to sterilize AM tissue grafts with good preservation of their biological features.²⁰

c. Preservation: Although non-preserved AM was used in some studies,^{21,22} it is generally recommended that AM is preserved for at least 4-6 months before the confirmation of the HIV negative status of the donor by repeated serology.^{18,23,24} The most common method of preservation is cryopreservation. The AM is mounted on a nitrocellulose filter paper is stored at -80 °C in a sterile vial containing Dulbecco modified Eagle medium and glycerol at the ratio of 1:1 (v/v). The cryopreservation of a suspension containing homogenized amniotic membrane was also reported in a small clinical trial.²⁵

AM can also be preserved under a freeze-dried (lyophilized)²⁶ or air-dried¹⁶ condition. Only one small study compared fresh and dried AM in the treatment of partial LSCD. The outcomes at 24 weeks were similar between these two preservation methods.²⁷

d. Removal of epithelium: According to different clinical purposes, AM (cryopreserved, lyophilized or dry) might be used as intact (with intact epithelium) or denuded (epithelium is removed). Denuded AM has been shown to have less immunogenicity, support the proliferation of LSCs better and preserve a higher clonogenicity.^{12,28} Removal of the epithelium could be accomplished by NaOH, urea (5M) treatment or mechanically scraping by using a cell scraper with or without the combination of trypsin, EDTA, dispase, or thermolysin.^{13,14,29-32}

e. Effect of AM preparation, sterilization and preservation on its biological properties: A laboratory study¹² compared the effect of different methods of epithelial removal (intact, partial denuded, fully denuded), sterilization (peracetic acid sterilized, nonperacetic acid sterilized) and cryopreservation (DMEM/glycerol, glycerol only, no glycerol) on AM and its impact on the cultured LSCs. The findings showed that complete

removal of epithelium facilitated the migration and confluence of LSCs and did not affect the biological properties of LSCs. However, the use of glycerol as a cryoprotectant seemed to impair the function of AM to support the growth of LSCs, leading to a poorer morphology of LSCs and a lower percentage of cells expressing LSC biomarkers. Moreover, sterilization by gamma irradiation has been shown to cause a significant decrease of growth factors and the structural alteration of basement membrane.^{33,34} The optimal method to prepare, sterilize and preserve AM still needs to be investigated to optimize the function of AM for different applications in ophthalmology.

B. Application of AM in surgical treatment of LSCD

1. Transplantation of AM alone

a. Indications: AM transplantation (AMT) is widely used in the treatment of acute phase of chemical burn, thermal injury or Stevens-Johnson Syndrome to promote epithelium healing, and alleviate ocular surface inflammation which might rescue the residual LSCs.^{21,22,35-37} In these cases, AM is serving as a temporary overlay patch to mechanically protect the ocular surface, promote normal epithelial wound healing and prevent intermediate-term ocular cicatricial sequelae.³⁷ However, prospective, randomized, controlled clinical trials showed that no definite long-term advantage of AMT alone over medical therapy in terms of final visual outcome, appearance of symblepharon and corneal vascularization.³⁸⁻⁴⁰

AM transplantation also have been used to treat partial LSCD.^{15,24,27,41-44} Although AM is believed to serve as the permanent graft in these cases and to provide a surrogate basement membrane for the regenerated epithelium, the histological study confirmed the complete integration of AM with corneal stromal tissue,⁴⁵ which suggests the effect of AM was more through its biological properties than mechanical properties.

b. Surgical technique: After debridement of fibrovascular pannus and removal of scarring and inflamed tissue, AM is removed from the storage medium, and placed over the denuded cornea, limbus and conjunctiva (Figure 1A). In a majority of studies, AM was placed with the epithelium/basement membrane side facing up.^{24,27,35-37,41,43,45-48} The placement of AM with the stromal side facing up was only used in only two studies.^{35,41} However, some studies did not specify the orientation of the basement membrane.^{15,49-51} AM was then secured to the cornea with 10-0 or 11-0 nylon sutures^{24,48} or/and to the surrounding conjunctiva with 9-0 or 10-0 Vicryl sutures.^{35,49} Recent studies showed that fibrin glue could be used to avoid suture-related disadvantages and complications.^{37,42}

Occasionally sectorial sequential conjunctival epitheliectomy (SSCE) combined with AMT is used in the treatment of partial LSCD.^{44,50} It is a surgical procedure in which the abnormal conjunctival epithelium on the cornea is removed by mechanical superficial debridement. The denuded corneal and limbal surface could be re-epithelialized by corneal epithelial cells that migrate from the unaffected area of cornea and limbus.⁵² The limitation of SSCE is that it could cause persistent epithelial defect and pain from the epithelial debridement. Multiple treatments are often required to achieve satisfactory outcome in

successful cases. The combined AMT might reduce bleeding, pain and promote epithelialization.

c. Outcome: As shown in Table 1, a total of 8 studies reported the outcome of AMT alone in the treatment of partial LSCD. After AMT for the treatment of partial LSCD, the mean time of complete corneal and conjunctival re-epithelialization is usually 2-3 weeks.^{15,24,43} The mean time of the maintenance of a stable corneal epithelial surface is 14-25 months after surgery, along with less stromal opacity and vascularization.^{24,46,47} Visual improvement is found in 25%-81% eyes.^{15,24,27,42,43,46,49} However, the long term success rate of AMT following superficial keratectomy in cases with partial LSCD is only 40%–54% at an average follow-up period of 52 months.⁴³

2. Direct transplantation of limbal tissues with AM

a. Indications: Direct LSCs transplantation includes conjunctival limbal autograft transplantation (CLAU), conjunctival limbal allograft transplantation (CLAL) and keratolimbal allograft transplantation (KLAL). Keratolimbal autograft transplantation (KLAU) has only been published by two case reports^{53,54} because of the requirement of large graft size (around 180 degree) on the donor eye and the need to reconstruct the conjunctiva in LSCD eyes with abnormal conjunctiva.

CLAU is usually performed in unilateral total LSCD cases, while CLAL and KLAL are considered in bilateral LSCD cases. All of these procedures can be performed with the combination of AMT.

b. Surgical technique

(1) *Under the limbal tissue in the recipient eye (inlay):* After the removal of conjunctival and dermal-like epithelium covering the cornea, the dissection of fibrous tissues and the releasement of existing symblephon, AM was placed on the denuded ocular surface and secured with suture or fibrin glue. Then the limbal graft is sutured to the original limbal area (Figure 1B).^{15,49,50,55-72} In these cases, AM is thought to reduce postoperative inflammation and scarring in the underlying stroma. Moreover, many researchers thought that a combination of AMT might secure an environment favorable for the regeneration of LSCs,^{58,64-66} thus reducing the requirement of graft size and decreasing the risk of iatrogenic of LSCD in the donor eye.

(2) *Covering the limbal tissue in the recipient eye (overlay):* After the fixation of limbal grafts, AM was used as a temporary patch to cover the limbal grafts and the entire ocular surface at the end of the surgery (Figure 1C).^{63,68,73-77} In some studies, AM are placed both under and over the limbal grafts, which is called “Sandwich” technique (Figure 1D).^{58,61,63-65,67,78} The role of AM in this condition is similar to the contact lens, which provides mechanical protection to the limbal grafts and regenerated epithelium from external insults, and relieves ocular symptoms such as pain, photophobia and discomfort after surgery.

(3) **Serving as the patch in the donor eye:** The efficacy of the transplantation of 2 clock hours (60°) of donor limbus for a permanent and stable epithelialization of the cornea has been reported.^{58,69} However, it is generally presumed that at least three to four clock hours (90°–120°) of a conjunctival–limbal graft is usually required to obtain enough amount of LSCs in the graft, either from the healthy contralateral eye (CLAU) or from an eye of a living relative (Ir-CLAL).^{15,46,66,79} Therefore, there is a risk of developing LSCD in the donor eye. In these cases, AM used as a temporary patch in the donor eye^{58,64} may be helpful to reduce the risk of iatrogenic LSCD after graft removal because AM is thought to provide support for restoring the remaining functional LSCs.^{36,64,68} However, all these reports are retrospective uncontrolled studies. There is no high-level data demonstrating the advantage of AMT in the donor eye.

(4) **CLAU combined with AM-assisted SSCE:** It is recently reported that a modified AM-assisted SSCE, named as amnion-assisted conjunctival epithelial redirection, could be combined with CLAU.^{80,81} It was advocated that AM might play a role in redirecting conjunctival epithelium and preventing admixtures of conjunctival epithelial cells and limbal explant-derived corneal epithelial cells on to the corneal surface.

c. Outcome

(1) **Conjunctival limbal autograft/conjunctival limbal allograft:** A total of 17 studies reported the outcome of CLAU/CLAL with or without combined AMT after the follow-up of 12 months. Among them, only two studies directly compared the outcome with or without the use of AM in CLAU/CLAL. Ivekovic et al⁴⁶ compared the time required to re-epithelialize after AMT, CLAU, and CLAU combined with AMT. The mean re-epithelialization time was 24.6 days, 14 days and 15.3 days in each group, respectively. There was no difference between CLAU and CLAU+AMT, both of which were shorter than AMT only. However, Barreiro et al⁵⁹ reported that although the final graft survival rate was similar between groups with or without the use of AMT, re-epithelialization time was significantly longer in the group using AMT.

The other studies are non-comparative studies. They only focused either on CLAU/CLAL with AMT,^{15,62,65-67,70,75,78,82} or CLAU/CLAL without AMT.⁸³⁻⁸⁸ Although a higher or similar successful rate with AMT (Table 2) was reported in the majority of studies, the study designs and patient populations were quite different (Table 1). Therefore, there is insufficient evidence to support the advantages of combined use of AMT in CLAU/CLAL either to promote epithelial healing or to increase the graft survival, even though AMT is used as a routine procedure in many cases of CLAU/CLAL.

(2) **Keratolimbal allograft:** A total of 16 studies reported the outcome of KLAL after the follow-up of 12 months, 10 studies with AMT,^{49,55,56,63,65,71,72,76,77,89} and 6 without AMT.^{88,90-94} No comparative studies have been performed yet. The successful rate of KLAL, no matter AMT is used or not, has a similar decreasing tendency with the prolongation of follow-up. Table 2 showed that AM played a minor role in the graft survival after KLAL. Although the authors suggested that the application of AM could reduce the

postoperative inflammation and complications in these cases, the function of AM in KLAL needs to be investigated by further comparative studies.

3. Transplantation of ex vivo cultured cells on AM

a. Indications and presumed function of AM: For patients who have bilateral total limbus damage without residual LSCs, or those who do not have enough healthy limbal tissue in the other eye to harvest sufficient amount of LSCs, transplantation of ex vivo cultured and expanded cells is one of main approaches for the treatment of LSCD to restore the structural and functional integrity of corneal surface. The most commonly used cell sources for transplantation are human limbal epithelium⁹⁵ and oral mucosal epithelium.³⁰ The procedure is called “cultivated limbal epithelial transplantation (CLET)” and “cultivated oral mucosal epithelial transplantation (COMET)” respectively. The applications of human bone marrow mesenchymal stem cells,⁹⁶ human conjunctival epithelial cells,⁹⁷ and human nasal mucosal epithelial cells⁹⁸ have also been reported. The cell source can be taken either from the patient (autologous), or from an eye of a living relative or cadaveric tissue (allogenic). The biggest advantages of this technique is the minimal need of donor tissue (less than 1mm²)^{99,100} and the lowest risk for the donor eye.

Many materials such as AM,^{95,100,101} fibrin sheet,^{99,102,103} contact lenses,¹⁰⁴ and nylon sheet¹⁰⁵ have been reported to serve as the substrate and carriers of cultured LSCs or oral mucosal epithelial cells. Among them, AM is still most commonly used. AM usually serves as a surrogate basement membrane for cultured cells and the substrate as a cell carrier in CLET or COMET. Although both de-epithelialized (denuded) and intact AM can be used, de-epithelialized AM is better than intact AM because it preserves the properties of LSCs better and facilitates the migration and confluence of LSCs.¹² Moreover, it has been reported that some limbal epithelial stem cells underwent epithelial-mesenchymal transition and invaded the limbal stroma when cultured on intact AM.²⁸

It has been shown that AM preferentially preserves and expands limbal epithelial cells that retain their in vivo properties of slow cycling, putative marker expression, and an undifferentiated state.^{6,106-114} The maintenance of a limbal epithelial phenotype indicates that AM provides a unique stromal microenvironment beneficial to the preservation and expansion of LSCs. AM also prevent cultured LSCs from undergoing apoptosis through interleukin-1 receptor antagonist.¹¹⁵

b. Methods of cultivation on AM: After the biopsy of limbus or oral mucosa, careful removal of excessive tissue, and rinsing with culture medium containing antibiotics, there are two methods to culture cells on AM. One is chopping the tissue into small pieces and then placing the explant on the epithelium/basement membrane side of AM.^{6,32,95,100,108-113,116-120} The orientation of limbal explant on AM, either epithelial side or stromal side facing up, does not influence tissue adhesion and cell expansion.¹⁰⁰ The other method is incubating the biopsy tissue with trypsin, EDTA and dispase to obtain single cell suspension first. Then these single cells are seeded on AM with or without the presence of irradiation- or mitomycin C-treated 3T3 feeder cells.^{30,96,107,110,121-131} These two methods do not have differences regarding the cell growth and phenotype.¹¹⁰

A minimum size of 0.3mm² live limbal tissue or 0.5mm² cadaveric limbal explant is required to achieve sufficient cells for expansion and transplantation.¹⁰⁰ Limbal explant takes more time to reach a linear growth phase if it is retrieved from corneo-limbal rings or discs with a longer duration of organ culture.¹³² As for oral mucosal biopsy, at least a specimen with the size of 2 ~3 mm² is needed.¹²² The successful rate of ex vivo cultured and expanded cells on AM is reported to be 96.2%-98.5%.^{6,112}

c. Surgical technique: Corneal fibrovascular tissue and perilimbal subconjunctival scarring tissue are dissected and removed to the bare sclera at least 2 to 3 mm behind the limbus. Symblepharon are released if necessary. Then cultured epithelial cell sheet, together with the amniotic membrane substrate, is placed on the cornea with the epithelial side up. The graft is secured with either suture or fibrin glue.

d. Outcome

(1) **CLET:** Owing to the small size of tissue needed for ex vivo culture and the fact that antigen presenting cells do not survive during culture,¹³³ the rejection rate of CLET is relatively low even in allogenic cases. The overall successful rate of CLET is stable after one year postoperatively.^{29,32,93,110,113,114,117-120,134-142,143,144} Nevertheless, the successful rate is influenced by many factors including age, donor source, and cell quality.^{99,117,120,134,136,137} it should be noted that the clinical outcomes of the transplantation of LSCs cultured on AM and fibrin are similar, as shown in Table 3. Fibrin is easier to be standardized, but AM has a wider accessibility, especially in the developing countries.

(2) **COMET:** The overall successful rate of COMET is stable after two years postoperatively.^{123,126,127,129,145} Although Kim¹⁴⁶ and Hirayama¹⁴⁷ reported that the transplantation of substrate-free oral mucosal cell sheet achieved better clinical outcomes (87.5% and 62.5%, respectively) than AM group (44%), the mean follow-up was only one year after surgery, as shown in Table 3. Its midterm and long-term outcome needs to be evaluated by further studies.

The result of immunostaining and RT-PCR showed that the oral mucosal epithelial cells cultured on AM expressed putative markers of progenitor stem cells, namely p63 and ABCG2, and markers of epithelial differentiation such as CK3 and connexin 43.^{123-125,127,128,148,149} However, neither CK12, the corneal epithelium-specific marker, nor Pax6, an eye-specific transcription factor, was expressed in these transplanted oral mucosal cells.¹⁵⁰ These results suggest that although oral mucosal epithelial cells cultured on AM achieved a similar phenotype of limbal and corneal epithelium, they do not undergo a true transdifferentiation.

4. Transplantation of in vivo expanded LSCs on AM

a. Indications: A novel surgical technique named as “simple limbal epithelial transplantation (SLET)” was firstly described by Sangwan.¹⁵¹ It allows the in vivo expansion of small pieces of limbal biopsy on AM, combining the advantages of CLAU (low cost, single staged, no requirement of clinical-grade laboratory) and CLET (using minimal

donor tissue). Both fresh AM and cryopreserved AM are applicable.^{151,152} This technique is mainly used in the treatment of unilateral LSCD.

b. Surgical technique: AM is considered to provide a suitable substrate and create a nourishing ocular surface microenvironment, allowing in-vivo expansion of LSCs from the donor tissue explants. In most SLET cases, AM is placed over the bare ocular surface and donor limbal lenticule is secured on AM with the epithelial side up (Figure 2A).^{75,151,153-155} Instead, Vasquez-Perez¹⁵⁶ and Vazirani¹⁵⁷ described a modified SLET. Donor tissue explants were placed on the bared cornea surface and AM is used to cover the grafts and entire corneal surface (Figure 2B). The authors believed that placing the AM either above or below the donor tissue explants is equally effective and safe. Amescua et al¹⁵² reported another modified SLET named as “sandwich technique” in which the limbal biopsy explants were placed between the two layers of AM with the intention of replicating a fetal environment for the stem cells (Figure 2C). This technique provides protection to the graft and stem cell niche without negative effect on the clinical outcome.

c. Outcome: SLET has an excellent outcome in the treatment of partial and total LSCD. The longest follow-up has been only 18 months (Table 1). Complete epithelialization is usually achieved within four weeks after surgery.¹⁵⁵ A stable and avascular corneal surface is found in 100% eyes at 6 months and 9 months, in 80% eyes at 12 months, and in 76% eyes at 18 months.^{75,153,154} AMT is used in all reported cases of SLET and the actual function of AMT in SLET is unknown.

IV. Conclusions

The surgical approaches to treat LSCD vary depending on the severity of LSCD. The transplantation of AM alone seems to have limited long term effect. AMT combined with various types of LSC transplantation is commonly performed based on the presumption that AM provides biologically and mechanically support, and protection to the transplanted tissues and cells. High level studies are lacking to support the efficacy of AMT in LSC transplantation. Future randomized controlled clinical trials are needed to demonstrate the efficacy of AMT in the treatment of LSCD.

Acknowledgement

The study is supported in part by an unrestricted grant from Research to Prevent Blindness to Stein Eye Institute. SXD received grant support from National Eye Institute (5P30EY000331 and R01EY021797), California Institute for Regenerative Medicine (TR2-01768, CLIN1-08686).

References:

1. Ramos T, Scott D, Ahmad S. An Update on Ocular Surface Epithelial Stem Cells: Cornea and Conjunctiva. *Stem cells international*. 2015;2015:601731. [PubMed: 26146504]
2. Le Q, Xu J, Deng SX. The diagnosis of limbal stem cell deficiency. *The ocular surface*. 2017.
3. Kim BY, Riaz KM, Bakhtiari P, et al. Medically reversible limbal stem cell disease: clinical features and management strategies. *Ophthalmology*. 2014;121(10):2053–2058. [PubMed: 24908203]
4. Fukuda K, Chikama T, Nakamura M, Nishida T. Differential distribution of sub-chains of the basement membrane components type IV collagen and laminin among the amniotic membrane, cornea and conjunctiva. *Cornea*. 1999;18:73–79. [PubMed: 9894941]

5. Rodriguez-Ares MT, Lopez-Valladares MJ, Tourino R, et al. Effects of lyophilization on human amniotic membrane. *Acta Ophthalmol.* 2009;87(4):396–403. [PubMed: 18937812]
6. Meller D, Pires RT, Tseng SC. Ex vivo preservation and expansion of human limbal epithelial stem cells on amniotic membrane cultures. *Br J Ophthalmol.* 2002;86(4):463–471. [PubMed: 11914219]
7. Yeh HJ, Yao CL, Chen HI, Cheng HC, Hwang SM. Cryopreservation of human limbal stem cells ex vivo expanded on amniotic membrane. *Cornea.* 2008;27(3):327–333. [PubMed: 18362662]
8. Malhotra C, Jain AK. Human amniotic membrane transplantation: Different modalities of its use in ophthalmology. *World Journal of Transplantation.* 2014;4(2):111. [PubMed: 25032100]
9. Tseng SC. HC-HA/PTX3 Purified From Amniotic Membrane as Novel Regenerative Matrix: Insight Into Relationship Between Inflammation and Regeneration. *Invest Ophthalmol Vis Sci.* 2016;57(5):ORSFh1–8. [PubMed: 27116665]
10. Chen SY, Han B, Zhu YT, et al. HC-HA/PTX3 Purified From Amniotic Membrane Promotes BMP Signaling in Limbal Niche Cells to Maintain Quiescence of Limbal Epithelial Progenitor/Stem Cells. *Stem Cells.* 2015;33(11):3341–3355. [PubMed: 26148958]
11. Lee S-H, Tseng SCG. Amniotic Membrane Transplantation for Persistent Epithelial Defects With Ulceration. *American Journal of Ophthalmology.* 1997;123(3):303–312. [PubMed: 9063239]
12. Shortt AJ, Secker GA, Lomas RJ, et al. The effect of amniotic membrane preparation method on its ability to serve as a substrate for the ex-vivo expansion of limbal epithelial cells. *Biomaterials.* 2009;30(6):1056–1065. [PubMed: 19019426]
13. Saghizadeh M, Winkler MA, Kramerov AA, et al. A simple alkaline method for decellularizing human amniotic membrane for cell culture. *PLoS One.* 2013;8(11):e79632. [PubMed: 24236148]
14. Mariappan I, Maddileti S, Savy S, et al. In vitro culture and expansion of human limbal epithelial cells. *Nat Protoc.* 2010;5(8):1470–1479. [PubMed: 20671730]
15. Gomes JA, dos Santos MS, Cunha MC, Mascaro VL, Barros Jde N, de Sousa LB. Amniotic membrane transplantation for partial and total limbal stem cell deficiency secondary to chemical burn. *Ophthalmology.* 2003;110(3):466–473. [PubMed: 12623806]
16. Singh R, Gupta P, Kumar P, Kumar A, Chacharkar MP. Properties of Air Dried Radiation Processed Amniotic Membranes under Different Storage Conditions. *Cell Tissue Bank.* 2003;4(2–4):95–100. [PubMed: 15256845]
17. Gajiwala K, Gajiwala AL. Evaluation of lyophilised, gamma-irradiated amnion as a biological dressing. *Cell Tissue Bank.* 2004;5(2):73–80. [PubMed: 15241002]
18. Jirsova K, Jones GLA. Amniotic membrane in ophthalmology: properties, preparation, storage and indications for grafting—a review. *Cell Tissue Bank.* 2017;18(2):193–204. [PubMed: 28255771]
19. von Versen-Hoyneck F, Syring C, Bachmann S, Moller DE. The influence of different preservation and sterilisation steps on the histological properties of amnion allografts—light and scanning electron microscopic studies. *Cell Tissue Bank.* 2004;5(1):45–56. [PubMed: 15256839]
20. Wehmeyer JL, Natesan S, Christy RJ. Development of a Sterile Amniotic Membrane Tissue Graft Using Supercritical Carbon Dioxide. *Tissue Eng Part C Methods.* 2015;21(7):649–659. [PubMed: 25471248]
21. Ucakhan OO, Koklu G, Firat E. Nonpreserved human amniotic membrane transplantation in acute and chronic chemical eye injuries. *Cornea.* 2002;21(2):169–172. [PubMed: 11862088]
22. Chen J, Zhou S, Huang T, Liu Z, Chen L, Lin Y. A clinical study on fresh amniotic membrane transplantation for treatment of severe ocular surface disorders at acute inflammatory and cicatricial stage. *Zhonghua Yan Ke Za Zhi.* 2000;36(1):13–17. [PubMed: 11853574]
23. Qureshi IZ, Fareeha A, Khan WA. Technique for Processing and Preservation of Human Amniotic Membrane for Ocular Surface Reconstruction *Int J Biotechnol Bioeng.* 2010;4(9):710–713.
24. Anderson DF, Ellies P, Pires RT, Tseng SC. Amniotic membrane transplantation for partial limbal stem cell deficiency. *Br J Ophthalmol.* 2001;85(5):567–575. [PubMed: 11316719]
25. Bonci P, Bonci P, Lia A. Suspension made with amniotic membrane: clinical trial. *Eur J Ophthalmol.* 2005;15(4):441–445.
26. Nakamura T, Yoshitani M, Rigby H, et al. Sterilized, freeze-dried amniotic membrane: a useful substrate for ocular surface reconstruction. *Invest Ophthalmol Vis Sci.* 2004;45(1):93–99. [PubMed: 14691159]

27. Chugh JP, Jain P, Sen R. Comparative analysis of fresh and dry preserved amniotic membrane transplantation in partial limbal stem cell deficiency. *Int Ophthalmol*. 2015;35(3):347–355. [PubMed: 24898773]
28. Li W, Hayashida Y, He H, Kuo CL, Tseng SC. The fate of limbal epithelial progenitor cells during explant culture on intact amniotic membrane. *Invest Ophthalmol Vis Sci*. 2007;48(2):605–613. [PubMed: 17251456]
29. Schwab IR, Reyes M, Isseroff RR. Successful transplantation of bioengineered tissue replacements in patients with ocular surface disease. *Cornea*. 2000; 19(4):421–426. [PubMed: 10928750]
30. Nakamura T, Inatomi T, Sotozono C, Amemiya T, Kanamura N, Kinoshita S. Transplantation of cultivated autologous oral mucosal epithelial cells in patients with severe ocular surface disorders. *Br J Ophthalmol*. 2004;88(10):1280–1284. [PubMed: 15377551]
31. Hopkinson A, Shanmuganathan V, Gray T, et al. Optimization of amniotic membrane (AM) denuding for tissue engineering. *Tissue Eng Part C Methods*. 2008;14(4):371–381. [PubMed: 18821842]
32. Sangwan VS, Matalia HP, Vemuganti GK, et al. Clinical outcome of autologous cultivated limbal epithelium transplantation. *Indian J Ophthalmol*. 2006;54(1):29–34. [PubMed: 16531667]
33. Paolin A, Trojan D, Leonardi A, et al. Cytokine expression and ultrastructural alterations in fresh-frozen, freeze-dried and gamma-irradiated human amniotic membranes. *Cell Tissue Bank*. 2016;17(3):399–406. [PubMed: 27072557]
34. Mrazova H, Koller J, Kubisova K, Fujerikova G, Klincova E, Babal P. Comparison of structural changes in skin and amnion tissue grafts for transplantation induced by gamma and electron beam irradiation for sterilization. *Cell Tissue Bank*. 2016;17(2):255–260. [PubMed: 26649556]
35. Meller D, Pires RT, Mack RJ, et al. Amniotic membrane transplantation for acute chemical or thermal burns. *Ophthalmology*. 2000;107(5):980–989; discussion 990. [PubMed: 10811094]
36. Tejwani S, Kolari RS, Sangwan VS, Rao GN. Role of amniotic membrane graft for ocular chemical and thermal injuries. *Cornea*. 2007;26(1):21–26. [PubMed: 17198009]
37. Sharma N, Thenarasun SA, Kaur M, et al. Adjuvant Role of Amniotic Membrane Transplantation in Acute Ocular Stevens-Johnson Syndrome: A Randomized Control Trial. *Ophthalmology*. 2016;123(3):484–491. [PubMed: 26686968]
38. Tamhane A, Vajpayee RB, Biswas NR, et al. Evaluation of amniotic membrane transplantation as an adjunct to medical therapy as compared with medical therapy alone in acute ocular burns. *Ophthalmology*. 2005; 112(11):1963–1969. [PubMed: 16198422]
39. Tandon R, Gupta N, Kalaivani M, Sharma N, Titiyal JS, Vajpayee RB. Amniotic membrane transplantation as an adjunct to medical therapy in acute ocular burns. *Br J Ophthalmol*. 2011;95(2):199–204. [PubMed: 20675729]
40. Sharma N, Singh D, Maharana PK, et al. Comparison of Amniotic Membrane Transplantation and Umbilical Cord Serum in Acute Ocular Chemical Burns: A Randomized Controlled Trial. *Am J Ophthalmol*. 2016;168:157–163. [PubMed: 27210276]
41. Saw VP, Minassian D, Dart JK, et al. Amniotic membrane transplantation for ocular disease: a review of the first 233 cases from the UK user group. *Br J Ophthalmol*. 2007;91 (8):1042–1047. [PubMed: 17314154]
42. Kheirkhah A, Casas V, Raju VK, Tseng SC. Sutureless amniotic membrane transplantation for partial limbal stem cell deficiency. *Am J Ophthalmol*. 2008;145(5):787–794. [PubMed: 18329626]
43. Konomi K, Satake Y, Shimmura S, Tsubota K, Shimazaki J. Long-term results of amniotic membrane transplantation for partial limbal deficiency. *Cornea*. 2013;32(8):1110–1115. [PubMed: 23615271]
44. Diaz-Valle D, Santos-Bueso E, Benitez-Del-Castillo JM, et al. [Sectorial conjunctival epitheliectomy and amniotic membrane transplantation for partial limbal stem cells deficiency]. *Arch Soc Esp Oftalmol*. 2007;82(12):769–772. [PubMed: 18040922]
45. Tosi GM, Traversi C, Schuerfeld K, et al. Amniotic membrane graft: histopathological findings in five cases. *J Cell Physiol*. 2005;202(3):852–857. [PubMed: 15481059]
46. Ivekovic R, Tedeschi-Reiner E, Novak-Laus K, Andrijevic-Derk B, Cima I, Mandic Z. Limbal graft and/or amniotic membrane transplantation in the treatment of ocular burns. *Ophthalmologica*. 2005;219(5):297–302. [PubMed: 16123557]

47. Lopez-Garcia JS, Rivas L, Garcia-Lozano I. [Moderate limbal deficiency in patients with congenital aniridia treated with amniotic membrane transplantation]. *Arch Soc Esp Oftalmol*. 2005;80(9):517–523. [PubMed: 16193434]
48. Westekemper H, Figueiredo FC, Siah WF, Wagner N, Steuhl KP, Meller D. Clinical outcomes of amniotic membrane transplantation in the management of acute ocular chemical injury. *Br J Ophthalmol*. 2017;101(2):103–107. [PubMed: 27150827]
49. Tseng SC, Prabhasawat P, Barton K, Gray T, Meller D. Amniotic membrane transplantation with or without limbal allografts for corneal surface reconstruction in patients with limbal stem cell deficiency. *Arch Ophthalmol*. 1998; 116(4):431–441. [PubMed: 9565039]
50. Burcu A, Yalniz-Akkaya Z, Ozdemir MF, Erdem E, Onat MM, Ornek F. Surgical rehabilitation following ocular chemical injury. *Cutan Ocul Toxicol*. 2014;33(1):42–48. [PubMed: 23713679]
51. Seitz B, Kasmann-Kellner B, Viestenz A. [Stage-related therapy of congenital aniridia]. *Ophthalmologie*. 2014; 111(12):1164–1171. [PubMed: 25475189]
52. Dua HS, Forrester JV. The corneoscleral limbus in human corneal epithelial wound healing. *Am J Ophthalmol*. 1990;110(6):646–656. [PubMed: 2248329]
53. Jarade E, Amro M, Haydar AA, Hemade A. Simultaneous Keratolimbal Autograft and Penetrating Autokeratoplasty: A Single-Stage Procedure to Restore Monocular Vision of a Blind Patient With Limbal Stem Cell Deficiency. *Cornea*. 2017;36(6):749–751. [PubMed: 28376025]
54. Celis Sanchez J, Mesa Varona DV, Avendano Cantos E, Lopez-Romero Moraleda S, Cebrian Rosado E, Gonzalez Del Valle F. Keratolimbal autograft transplantation as a possible new treatment of Lisch epithelial corneal dystrophy. *Arch Soc Esp Oftalmol*. 2016;91(7):333–336. [PubMed: 26928889]
55. Tsubota K, Satake Y, Kaido M, et al. Treatment of severe ocular-surface disorders with corneal epithelial stem-cell transplantation. *N Engl J Med*. 1999;340(22):1697–1703. [PubMed: 10352161]
56. Solomon A, Ellies P, Anderson DF, et al. Long-term outcome of keratolimbal allograft with or without penetrating keratoplasty for total limbal stem cell deficiency. *Ophthalmology*. 2002;109(6):1159–1166. [PubMed: 12045060]
57. Stoiber J, Muss WH, Pohla-Gubo G, Ruckhofer J, Grabner G. Histopathology of human corneas after amniotic membrane and limbal stem cell transplantation for severe chemical burn. *Cornea*. 2002;21(5):482–489. [PubMed: 12072723]
58. Kheirkhah A, Raju VK, Tseng SC. Minimal conjunctival limbal autograft for total limbal stem cell deficiency. *Cornea*. 2008;27(6):730–733. [PubMed: 18580269]
59. Barreiro TP, Santos MS, Vieira AC, de Nadai Barros J, Hazarbassanov RM, Gomes JA. Comparative study of conjunctival limbal transplantation not associated with the use of amniotic membrane transplantation for treatment of total limbal deficiency secondary to chemical injury. *Cornea*. 2014;33(7):716–720. [PubMed: 24831198]
60. Capozzi P, Petroni S, Buzzonetti L. Combined HLA matched limbal stem cells allograft with amniotic membrane transplantation as a prophylactic surgical procedure to prevent corneal graft rejection after penetrating keratoplasty: case report. *Ann Ist Super Sanita*. 2014;50(3):298–300. [PubMed: 25292278]
61. Liang L, Sheha H, Tseng SC. Long-term outcomes of keratolimbal allograft for total limbal stem cell deficiency using combined immunosuppressive agents and correction of ocular surface deficits. *Arch Ophthalmol*. 2009;127(11):1428–1434. [PubMed: 19901207]
62. Lopez-Garcia JS, Rivas L, Garcia-Lozano I. [Severe limbal deficiency treated by combined limbal allograft and amniotic membrane transplantation]. *Arch Soc Esp Oftalmol*. 2005;80(7):405–412. [PubMed: 16059817]
63. Maruyama-Hosoi F, Shimazaki J, Shimmura S, Tsubota K. Changes observed in keratolimbal allograft. *Cornea*. 2006;25(4):377–382. [PubMed: 16670472]
64. Meallet MA, Espana EM, Grueterich M, Ti SE, Goto E, Tseng SC. Amniotic membrane transplantation with conjunctival limbal autograft for total limbal stem cell deficiency. *Ophthalmology*. 2003;110(8):1585–1592. [PubMed: 12917178]

65. Shimazaki J, Shimmura S, Tsubota K. Donor source affects the outcome of ocular surface reconstruction in chemical or thermal burns of the cornea. *Ophthalmology*. 2004;111(1):38–44. [PubMed: 14711712]
66. Santos MS, Gomes JA, Hofling-Lima AL, Rizzo LV, Romano AC, Belfort R Jr. Survival analysis of conjunctival limbal grafts and amniotic membrane transplantation in eyes with total limbal stem cell deficiency. *Am J Ophthalmol*. 2005;140(2):223–230. [PubMed: 16023069]
67. Moreira PB, Magalhaes RS, Pereira NC, Oliveira LA, Sousa LB. Limbal transplantation at a tertiary hospital in Brazil: a retrospective study. *Arq Bras Oftalmol*. 2015;78(4):207–211. [PubMed: 26375332]
68. Park G, Je J, Kim J. Stepwise surgical approach for in vivo expansion of epithelial stem cells to treating severe acute chemical burns with total limbal deficiency. *Korean J Ophthalmol*. 2003;17(2):75–82. [PubMed: 14717484]
69. Baradaran-Rafii A, Akbari M, Shirzadeh E, Shams M. Single block conjunctival limbal autograft for unilateral total limbal stem cell deficiency. *J Ophthalmic Vis Res*. 2015;10(1):90–92. [PubMed: 26005561]
70. Scocco C, Kwitko S, Rymer S, Marinho D, Bocaccio F, Lindenmeyer R. HLA-matched living-related conjunctival limbal allograft for bilateral ocular surface disorders: long-term results. *Arq Bras Oftalmol*. 2008;71(6):781–787. [PubMed: 19169506]
71. Han ES, Wee WR, Lee JH, Kim MK. Long-term outcome and prognostic factor analysis for keratolimbal allografts. *Graefes Arch Clin Exp Ophthalmol*. 2011;249(11):1697–1704. [PubMed: 21837442]
72. Ilari L, Daya SM. Long-term outcomes of keratolimbal allograft for the treatment of severe ocular surface disorders. *Ophthalmology*. 2002;109(7):1278–1284. [PubMed: 12093650]
73. Espana EM, Grueterich M, Ti SE, Tseng SC. Phenotypic study of a case receiving a keratolimbal allograft and amniotic membrane for total limbal stem cell deficiency. *Ophthalmology*. 2003;110(3):481–486. [PubMed: 12623808]
74. Kafle PA, Singh SK, Sarkar I, Surin L. Amniotic membrane transplantation with and without limbal stem cell transplantation in chemical eye injury. *Nepal J Ophthalmol*. 2015;7(1):52–55. [PubMed: 26695606]
75. Arora R, Dokania P, Manudhane A, Goyal JL. Preliminary results from the comparison of simple limbal epithelial transplantation with conjunctival limbal autologous transplantation in severe unilateral chronic ocular burns. *Indian J Ophthalmol*. 2017;65(1):35–40. [PubMed: 28300738]
76. Shi W, Gao H, Wang T, Xie L. Combined penetrating keratoplasty and keratolimbal allograft transplantation in comparison with corneoscleral transplantation in the treatment of severe eye burns. *Clin Exp Ophthalmol*. 2008;36(6):501–507. [PubMed: 18954310]
77. Eberwein P, Bohringer D, Schwartzkopff J, Birnbaum F, Reinhard T. Allogenic limbo-keratoplasty with conjunctivoplasty, mitomycin C, and amniotic membrane for bilateral limbal stem cell deficiency. *Ophthalmology*. 2012;119(5):930–937. [PubMed: 22330963]
78. Baradaran-Rafii A, Eslani M, Jamali H, Karimian F, Taylor UA, Djalilian AR. Postoperative complications of conjunctival limbal autograft surgery. *Cornea*. 2012;31(8):893–899. [PubMed: 22236787]
79. Cheung AY, Sarnicola E, Holland EJ. Long-Term Ocular Surface Stability in Conjunctival Limbal Autograft Donor Eyes. *Cornea*. 2017;36(9):1031–1035. [PubMed: 28644241]
80. Dua HS, Miri A, Elalfy MS, Lencova A, Said DG. Amnion-assisted conjunctival epithelial redirection in limbal stem cell grafting. *Br J Ophthalmol*. 2017;101(7):913–919. [PubMed: 27888184]
81. Mataix B, Alcantara A, Caro M, Montero J, Ponte B, Rodriguez de la Rua E. Variations in the technique for autologous limbal transplantation. *Arch Soc Esp Oftalmol*. 2016;91(10):501–504. [PubMed: 27156033]
82. Miri A, Al-Deiri B, Dua HS. Long-term outcomes of autolimbal and allolimbal transplants. *Ophthalmology*. 2010; 117(6):1207–1213. [PubMed: 20163866]
83. Ozdemir O, Tekeli O, Ornek K, Arslanpence A, Yalcindag NF. Limbal autograft and allograft transplantations in patients with corneal burns. *Eye (Lond)*. 2004;18(3):241–248. [PubMed: 15004571]

84. Torres J, Fernandez I, Quadrado MJ, et al. [Limbal transplantation: multicenter retrospective case series analysis]. *Arch Soc Esp Ophthalmol*. 2008;83(7):417–422. [PubMed: 18592441]
85. Kenyon KR, Tseng SC. Limbal autograft transplantation for ocular surface disorders. *Ophthalmology*. 1989;96(5):709–722; discussion 722–703. [PubMed: 2748125]
86. Wylegala E, Dobrowolski D, Tarnawska D, et al. Limbal stem cells transplantation in the reconstruction of the ocular surface: 6 years experience. *Eur J Ophthalmol*. 2008; 18(6):886–890. [PubMed: 18988157]
87. Javadi MA, Jafarinasab MR, Feizi S, Karimian F, Negahban K. Management of mustard gas-induced limbal stem cell deficiency and keratitis. *Ophthalmology*. 2011;118(7):1272–1281. [PubMed: 21397949]
88. Titiyal JS, Sharma N, Agarwal AK, Prakash G, Tandon R, Vajpayee R. Live Related versus Cadaveric Limbal Allograft in Limbal Stem Cell Deficiency. *Ocul Immunol Inflamm*. 2015;23(3): 232–239. [PubMed: 25058380]
89. Baradaran-Rafii A, Eslani M, Djalilian AR. Complications of keratolimbal allograft surgery. *Cornea*. 2013;32(5):561–566. [PubMed: 23073489]
90. Qi X, Xie L, Cheng J, Zhao J. Clinical results and influential factors of modified large-diameter lamellar keratoplasty in the treatment of total limbal stem cell deficiency. *Cornea*. 2013;32(5):555–560. [PubMed: 22580444]
91. Shen C, Chan CC, Holland EJ. Limbal Stem Cell Transplantation for Soft Contact Lens Wear-Related Limbal Stem Cell Deficiency. *Am J Ophthalmol*. 2015; 160(6):1142–1149 e1141. [PubMed: 26299533]
92. Holland EJ, Djalilian AR, Schwartz GS. Management of aniridic keratopathy with keratolimbal allograft: a limbal stem cell transplantation technique. *Ophthalmology*. 2003; 110(1):125–130. [PubMed: 12511357]
93. Parihar JKS, Parihar AS, Jain VK, Kaushik J, Nath P. Allogenic cultivated limbal stem cell transplantation versus cadaveric keratolimbal allograft in ocular surface disorder: 1-year outcome. *Int Ophthalmol*. 2017;37(6):1323–1331. [PubMed: 28025793]
94. Nassiri N, Pandya HK, Djalilian AR. Limbal allograft transplantation using fibrin glue. *Arch Ophthalmol*. 2011;129(2):218–222. [PubMed: 21320970]
95. Tsai RJ, Li LM, Chen JK. Reconstruction of damaged corneas by transplantation of autologous limbal epithelial cells. *N Engl J Med*. 2000;343(2):86–93. [PubMed: 10891515]
96. Rohaina CM, Then KY, Ng AM, et al. Reconstruction of limbal stem cell deficient corneal surface with induced human bone marrow mesenchymal stem cells on amniotic membrane. *Transl Res*. 2014;163(3):200–210. [PubMed: 24286920]
97. Silber PC, Ricardo JR, Cristovam PC, Hazarbassanov RM, Dreyfuss JL, Gomes JA. Conjunctival epithelial cells cultivated ex vivo from patients with total limbal stem cell deficiency. *Eur J Ophthalmol*. 2014:0.
98. Kim JH, Chun YS, Lee SH, et al. Ocular surface reconstruction with autologous nasal mucosa in cicatricial ocular surface disease. *Am J Ophthalmol*. 2010;149(1):45–53. [PubMed: 19875092]
99. Rama P, Matuska S, Paganoni G, Spinelli A, De Luca M, Pellegrini G. Limbal stem-cell therapy and long-term corneal regeneration. *N Engl J Med*. 2010;363(2):147–155. [PubMed: 20573916]
100. Kethiri AR, Basu S, Shukla S, Sangwan VS, Singh V. Optimizing the role of limbal explant size and source in determining the outcomes of limbal transplantation: An in vitro study. *PLoS One*. 2017;12(9):e0185623. [PubMed: 28957444]
101. Shortt AJ, Secker GA, Rajan MS, et al. Ex vivo expansion and transplantation of limbal epithelial stem cells. *Ophthalmology*. 2008; 115(11):1989–1997. [PubMed: 18554721]
102. Fasolo A, Pedrotti E, Passilongo M, et al. Safety outcomes and long-term effectiveness of ex vivo autologous cultured limbal epithelial transplantation for limbal stem cell deficiency. *Br J Ophthalmol*. 2017;101(5):640–649. [PubMed: 27543289]
103. Rama P, Bonini S, Lambiase A, et al. Autologous fibrin-cultured limbal stem cells permanently restore the corneal surface of patients with total limbal stem cell deficiency. *Transplantation*. 2001;72(9):1478–1485. [PubMed: 11707733]

104. Di Girolamo N, Bosch M, Zamora K, Coroneo MT, Wakefield D, Watson SL. A contact lens-based technique for expansion and transplantation of autologous epithelial progenitors for ocular surface reconstruction. *Transplantation*. 2009;87(10):1571–1578. [PubMed: 19461496]
105. Daya SM, Watson A, Sharpe JR, et al. Outcomes and DNA analysis of ex vivo expanded stem cell allograft for ocular surface reconstruction. *Ophthalmology*. 2005;112(3):470–477. [PubMed: 15745776]
106. Grueterich M, Tseng SC. Human limbal progenitor cells expanded on intact amniotic membrane ex vivo. *Arch Ophthalmol*. 2002;120(6):783–790. [PubMed: 12049584]
107. Harkin DG, Barnard Z, Gillies P, Ainscough SL, Apel AJ. Analysis of p63 and cytokeratin expression in a cultivated limbal autograft used in the treatment of limbal stem cell deficiency. *Br J Ophthalmol*. 2004;88(9):1154–1158. [PubMed: 15317707]
108. Lim MN, Umopathy T, Baharuddin PJ, Zubaidah Z. Characterization and safety assessment of bioengineered limbal epithelium. *Med J Malaysia*. 2011;66(4):335–341. [PubMed: 22299553]
109. Pathak M, Olstad OK, Drolsum L, et al. The effect of culture medium and carrier on explant culture of human limbal epithelium: A comparison of ultrastructure, keratin profile and gene expression. *Exp Eye Res*. 2016;153:122–132. [PubMed: 27702552]
110. Shimazaki J, Higa K, Morito F, et al. Factors influencing outcomes in cultivated limbal epithelial transplantation for chronic cicatricial ocular surface disorders. *Am J Ophthalmol*. 2007;143(6):945–953. [PubMed: 17459317]
111. Dhamodaran K, Subramani M, Matalia H, Jayadev C, Shetty R, Das D. One for all: A standardized protocol for ex vivo culture of limbal, conjunctival and oral mucosal epithelial cells into corneal lineage. *Cytherapy*. 2016;18(4):546–561. [PubMed: 26971683]
112. Fatima A, Sangwan VS, Iftekhar G, et al. Technique of cultivating limbal derived corneal epithelium on human amniotic membrane for clinical transplantation. *J Postgrad Med*. 2006;52(4):257–261. [PubMed: 17102542]
113. Sharma S, Tandon R, Mohanty S, et al. Culture of corneal limbal epithelial stem cells: experience from benchtop to bedside in a tertiary care hospital in India. *Cornea*. 2011;30(11):1223–1232. [PubMed: 21808195]
114. Zakaria N, Possemiers T, Dhubhghail SN, et al. Results of a phase I/II clinical trial: standardized, non-xenogenic, cultivated limbal stem cell transplantation. *J Transl Med*. 2014;12:58. [PubMed: 24589151]
115. Sun CC, Su Pang JH, Cheng CY, et al. Interleukin-1 receptor antagonist (IL-1RA) prevents apoptosis in ex vivo expansion of human limbal epithelial cells cultivated on human amniotic membrane. *Stem Cells*. 2006;24(9):2130–2139. [PubMed: 16741227]
116. Pauklin M, Kakkassery V, Steuhl KP, Meller D. Expression of membrane-associated mucins in limbal stem cell deficiency and after transplantation of cultivated limbal epithelium. *Curr Eye Res*. 2009;34(3):221–230. [PubMed: 19274530]
117. Ganger A, Vanathi M, Mohanty S, Tandon R. Long-Term Outcomes of Cultivated Limbal Epithelial Transplantation: Evaluation and Comparison of Results in Children and Adults. *Biomed Res Int*. 2015;2015:480983. [PubMed: 26770973]
118. Subramaniam SV, Sejpal K, Fatima A, Gaddipati S, Vemuganti GK, Sangwan VS. Coculture of autologous limbal and conjunctival epithelial cells to treat severe ocular surface disorders: long-term survival analysis. *Indian J Ophthalmol*. 2013;61(5):202–207. [PubMed: 23552358]
119. Ramirez BE, Sanchez A, Herreras JM, et al. Stem Cell Therapy for Corneal Epithelium Regeneration following Good Manufacturing and Clinical Procedures. *Biomed Res Int*. 2015;2015:408495. [PubMed: 26451369]
120. Sangwan VS, Basu S, Vemuganti GK, et al. Clinical outcomes of xeno-free autologous cultivated limbal epithelial transplantation: a 10-year study. *Br J Ophthalmol*. 2011;95(11):1525–1529. [PubMed: 21890785]
121. Balasubramanian S, Jasty S, Sitalakshmi G, Madhavan HN, Krishnakumar S. Influence of feeder layer on the expression of stem cell markers in cultured limbal corneal epithelial cells. *Indian J Med Res*. 2008;128(5):616–622. [PubMed: 19179682]

122. Ang LP, Nakamura T, Inatomi T, et al. Autologous serum-derived cultivated oral epithelial transplants for severe ocular surface disease. *Arch Ophthalmol*. 2006; 124(11):1543–1551. [PubMed: 17102000]
123. Dobrowolski D, Orzechowska-Wylegala B, Wowra B, et al. Cultivated Oral Mucosa Epithelium in Ocular Surface Reconstruction in Aniridia Patients. *Biomed Res Int*. 2015;2015:281870. [PubMed: 26451366]
124. Kolli S, Ahmad S, Mudhar HS, Meeny A, Lako M, Figueiredo FC. Successful application of ex vivo expanded human autologous oral mucosal epithelium for the treatment of total bilateral limbal stem cell deficiency. *Stem Cells*. 2014;32(8):2135–2146. [PubMed: 24590515]
125. Ma DH, Kuo MT, Tsai YJ, et al. Transplantation of cultivated oral mucosal epithelial cells for severe corneal burn. *Eye (Lond)*. 2009;23(6):1442–1450. [PubMed: 19373264]
126. Nakamura T, Takeda K, Inatomi T, Sotozono C, Kinoshita S. Long-term results of autologous cultivated oral mucosal epithelial transplantation in the scar phase of severe ocular surface disorders. *Br J Ophthalmol*. 2011;95(7):942–946. [PubMed: 21097786]
127. Prabhasawat P, Ekpo P, Uiprasertkul M, et al. Long-term result of autologous cultivated oral mucosal epithelial transplantation for severe ocular surface disease. *Cell Tissue Bank*. 2016;17(3):491–503. [PubMed: 27507558]
128. Priya CG, Arpitha P, Vaishali S, et al. Adult human buccal epithelial stem cells: identification, ex vivo expansion, and transplantation for corneal surface reconstruction. *Eye (Lond)*. 2011;25(12):1641–1649. [PubMed: 21941360]
129. Satake Y, Higa K, Tsubota K, Shimazaki J. Long-term outcome of cultivated oral mucosal epithelial sheet transplantation in treatment of total limbal stem cell deficiency. *Ophthalmology*. 2011;118(8):1524–1530. [PubMed: 21571372]
130. Sotozono C, Inatomi T, Nakamura T, et al. Cultivated oral mucosal epithelial transplantation for persistent epithelial defect in severe ocular surface diseases with acute inflammatory activity. *Acta Ophthalmol*. 2014;92(6):e447–453. [PubMed: 24835597]
131. Takeda K, Nakamura T, Inatomi T, Sotozono C, Watanabe A, Kinoshita S. Ocular surface reconstruction using the combination of autologous cultivated oral mucosal epithelial transplantation and eyelid surgery for severe ocular surface disease. *Am J Ophthalmol*. 2011;152(2):195–201 e191. [PubMed: 21652025]
132. Baylis O, Rooney P, Figueiredo F, Lako M, Ahmad S. An investigation of donor and culture parameters which influence epithelial outgrowths from cultured human cadaveric limbal explants. *J Cell Physiol*. 2013;228(5):1025–1030. [PubMed: 23042632]
133. Shortt AJ, Tuft SJ, Daniels JT. Corneal stem cells in the eye clinic. *British medical bulletin*. 2011;100:209–225. [PubMed: 21926089]
134. Sejjal K, Ali MH, Maddileti S, et al. Cultivated limbal epithelial transplantation in children with ocular surface burns. *JAMA Ophthalmol*. 2013; 131(6):731–736. [PubMed: 23559315]
135. Basu S, Ali H, Sangwan VS. Clinical outcomes of repeat autologous cultivated limbal epithelial transplantation for ocular surface burns. *Am J Ophthalmol*. 2012;153(4):643–650, 650 e641–642. [PubMed: 22265153]
136. Basu S, Fernandez MM, Das S, Gaddipati S, Vemuganti GK, Sangwan VS. Clinical outcomes of xeno-free allogeneic cultivated limbal epithelial transplantation for bilateral limbal stem cell deficiency. *Br J Ophthalmol*. 2012;96(12):1504–1509. [PubMed: 22976585]
137. Pauklin M, Fuchsluger TA, Westekemper H, Steuhl KP, Meller D. Midterm results of cultivated autologous and allogeneic limbal epithelial transplantation in limbal stem cell deficiency. *Dev Ophthalmol*. 2010;45:57–70. [PubMed: 20502027]
138. Prabhasawat P, Ekpo P, Uiprasertkul M, Chotikavanich S, Tesavibul N. Efficacy of cultivated corneal epithelial stem cells for ocular surface reconstruction. *Clin Ophthalmol*. 2012;6:1483–1492. [PubMed: 23055668]
139. Scholz SL, Thomasen H, Hestermann K, Dekowski D, Steuhl KP, Meller D. [Long-term results of autologous transplantation of limbal epithelium cultivated ex vivo for limbal stem cell deficiency]. *Ophthalmologe*. 2016;113(4):321–329. [PubMed: 26271737]

140. Cheng J, Zhai H, Wang J, Duan H, Zhou Q. Long-term outcome of allogeneic cultivated limbal epithelial transplantation for symblepharon caused by severe ocular burns. *BMC Ophthalmol.* 2017; 17(1):8. [PubMed: 28143466]
141. Meller D, Pauklin M, Westekemper H, Steuhl KP. [Autologous transplantation of cultivated limbal epithelium]. *Ophthalmologe.* 2010; 107(12):1133–1138. [PubMed: 20632012]
142. Vazirani J, Basu S, Kenia H, et al. Unilateral partial limbal stem cell deficiency: contralateral versus ipsilateral autologous cultivated limbal epithelial transplantation. *Am J Ophthalmol.* 2014;157(3):584–590 e581-582. [PubMed: 24269851]
143. Qi X, Xie L, Cheng J, Zhai H, Zhou Q. Characteristics of immune rejection after allogeneic cultivated limbal epithelial transplantation. *Ophthalmology.* 2013;120(5):931–936. [PubMed: 23380470]
144. Koizumi N, Inatomi T, Suzuki T, Sotozono C, Kinoshita S. Cultivated corneal epithelial stem cell transplantation in ocular surface disorders. *Ophthalmology.* 2001;108(9):1569–1574. [PubMed: 11535452]
145. Inatomi T, Nakamura T, Koizumi N, Sotozono C, Yokoi N, Kinoshita S. Midterm results on ocular surface reconstruction using cultivated autologous oral mucosal epithelial transplantation. *Am J Ophthalmol.* 2006;141(2):267–275. [PubMed: 16458679]
146. Kim YJ, Lee HJ, Ryu JS, et al. Prospective Clinical Trial of Corneal Reconstruction With Biomaterial-Free Cultured Oral Mucosal Epithelial Cell Sheets. *Cornea.* 2018;37(1):76–83. [PubMed: 29040119]
147. Hirayama M, Satake Y, Higa K, Yamaguchi T, Shimazaki J. Transplantation of cultivated oral mucosal epithelium prepared in fibrin-coated culture dishes. *Invest Ophthalmol Vis Sci.* 2012;53(3):1602–1609. [PubMed: 22323487]
148. Inatomi T, Nakamura T, Kojyo M, Koizumi N, Sotozono C, Kinoshita S. Ocular surface reconstruction with combination of cultivated autologous oral mucosal epithelial transplantation and penetrating keratoplasty. *Am J Ophthalmol.* 2006;142(5):757–764. [PubMed: 16989763]
149. Sen S, Sharma S, Gupta A, et al. Molecular characterization of explant cultured human oral mucosal epithelial cells. *Invest Ophthalmol Vis Sci.* 2011;52(13):9548–9554. [PubMed: 22064988]
150. Madhira SL, Vemuganti G, Bhaduri A, Gaddipati S, Sangwan VS, Ghanekar Y. Culture and characterization of oral mucosal epithelial cells on human amniotic membrane for ocular surface reconstruction. *Mol Vis.* 2008;14:189–196. [PubMed: 18334934]
151. Sangwan VS, Basu S, MacNeil S, Balasubramanian D. Simple limbal epithelial transplantation (SLET): a novel surgical technique for the treatment of unilateral limbal stem cell deficiency. *Br J Ophthalmol.* 2012;96(7):931–934. [PubMed: 22328817]
152. Amescua G, Atallah M, Nikpoor N, Galor A, Perez VL. Modified simple limbal epithelial transplantation using cryopreserved amniotic membrane for unilateral limbal stem cell deficiency. *Am J Ophthalmol.* 2014;158(3):469–475 e462. [PubMed: 24932987]
153. Basu S, Sureka SP, Shanbhag SS, Kethiri AR, Singh V, Sangwan VS. Simple Limbal Epithelial Transplantation: Long-Term Clinical Outcomes in 125 Cases of Unilateral Chronic Ocular Surface Burns. *Ophthalmology.* 2016;123(5):1000–1010. [PubMed: 26896125]
154. Vazirani J, Ali MH, Sharma N, et al. Autologous simple limbal epithelial transplantation for unilateral limbal stem cell deficiency: multicentre results. *Br J Ophthalmol.* 2016;100(10):1416–1420. [PubMed: 26817481]
155. Iyer G, Srinivasan B, Agarwal S, Tarigopula A. Outcome of allo simple limbal epithelial transplantation (alloSLET) in the early stage of ocular chemical injury. *Br J Ophthalmol.* 2017;101(6):828–833. [PubMed: 28407620]
156. Vasquez-Perez A, Nanavaty MA. Modified Allogenic Simple Limbal Epithelial Transplantation Followed by Keratoplasty as Treatment for Total Limbal Stem Cell Deficiency. *Ocul Immunol Inflamm.* 2017:1–3.
157. Vazirani J, Lal I, Sangwan V Customised simple limbal epithelial transplantation for recurrent limbal stem cell deficiency. *BMJ Case Rep.* 2015;2015.

158. Marchini G, Pedrotti E, Pedrotti M, et al. Long-term effectiveness of autologous cultured limbal stem cell grafts in patients with limbal stem cell deficiency due to chemical burns. *Clin Exp Ophthalmol*. 2012;40(3):255–267. [PubMed: 21668791]
159. Pellegrini G, Rama P, Matuska S, et al. Biological parameters determining the clinical outcome of autologous cultures of limbal stem cells. *Regen Med*. 2013;8(5):553–567. [PubMed: 23725042]
160. Burillon C, Huot L, Justin V, et al. Cultured autologous oral mucosal epithelial cell sheet (CAOMECS) transplantation for the treatment of corneal limbal epithelial stem cell deficiency. *Invest Ophthalmol Vis Sci*. 2012;53(3):1325–1331. [PubMed: 22064987]




Figure 1.

Schematic diagram of amniotic membrane transplantation (AMT) alone (A) and combination of direct limbal transplantation with AMT (B to D). In AMT alone procedure, AM depicted in blue is placed over the denuded cornea, limbus and conjunctiva (A). When combined with limbal stem cell transplantation, AM is either serving as a graft under the limbal tissues depicted in red (B), or as a patch covering the limbal tissues (C). In “Sandwich” technique, AM is placed both beneath and on top of the limbal grafts. The AMs beneath and on top of the limbal tissues are labeled as blue and orange, respectively (D).




Figure 2.

Schematic diagram of different surgical techniques of SLET

In a standard SLET (A), AM depicted in blue is placed on top of the ocular surface and donor limbal biopsy explants depicted in red are secured on AM. In a modified SLET (B), donor limbal biopsy explants are placed on the bared cornea surface and AM covers the limbal grafts and the entire corneal surface. The technique in which AMs are both used beneath (blue) and on top of (orange) the limbal tissues is called “Sandwich” technique (C).

Table 1
Demographic characteristics of studies with AMT involved in the treatment of limbal stem cell deficiency

Author (Year)	Study Type	No. of Eyes	Gender		Mean Age	Chemical/Thermal Injury	Etiology			Range of LSCD		
			Male	Female			Chronic cicatricial inflammation (SJS/OCP)	Others	Total	Partial	Follow-up in Months	
AMT alone												
Chung JP. 2015	P	30	15	15	48.9±16.3	3	7	30	0	30	0	6
Konomi K. 2013	R	16	9	7	57.4±16.4	2	2	12	0	16	0	52.3±26.3
Kheirkhah A. 2008	R	11	5	6	32.4±18.4	3	2	6	0	11	0	14.2±7.7
Lopez-Garcia JS. 2005	P	14	ND	ND	37	0	0	14	ND	ND	ND	24
Ivekovic R. 2005	ND	5	3	2	31.6±12.3	5	0	0	0	ND	ND	18±4.3
Gomes JA. 2003	P	4	4	0	34.5±26.3	4	0	0	0	4	0	17.5±5.1
Anderson DF. 2001	R	17	9	8	42.3±4.6	8	0	9	0	17	0	25.8±2.5
Tseng SC. 1998	R	10	4	6	36.8±8.4	4	0	6	0	ND	ND	12.3±9.3
CLAU/CLAL+AMT												
Arora R. 2017	P	10	ND	ND	18±8	10	0	0	0	3	7	6
Moreira PB. 2015	R	28	19	9	40.3	20	3	5	ND	ND	ND	24.8
Barreiro TP. 2014	R	15	13	2	36.3	15	0	0	0	15	0	19.7±5.6
Baradaran-Rafii. 2012	P	34	32	2	27.3±9.4	34	0	0	0	ND	ND	17.2±6.3
Miri A. 2010	R	27	19	8	ND	14	0	13	27	0	0	38±35.9
Scocco C. 2008	R	39	ND	ND	33.6±18.9	12	15	12	ND	ND	ND	48.7±30.6
Santos MS. 2005	P	33	26	5	35±16	22	11	0	33	0	0	33±12
Lopez-Garcia JS. 2005	P	14	ND	ND	47	7	2	5	14	0	0	24
Ivekovic R. 2005	ND	4	4	0	27.8±7.8	4	0	0	ND	ND	ND	12.8±1.7
Shimazaki J. 2004	R	11	11	1	40.2±14.3	11	0	0	11	0	0	15
Gomes JA. 2003	P	16	15	1	42.3±11.2	16	0	0	16	0	0	18.3±6.1
KLAL+AMT												
Baradaran-Rafii. 2013	R	45	41	4	26.7±8.7	41	4	0	0	ND	ND	26.1±11.8
Eberwein P. 2012	R	20	13	7	44	8	6	6	20	0	0	22.4
Han ES. 2011	R	24	17	5	39.4±17.4	8	8	8	ND	ND	ND	47.3±22
Shi W. 2008	R	39	33	5	ND	39	0	0	28	11	0	32

Author (Year)	Study Type	No. of Eyes	Gender			Mean Age	Chemical/Thermal Injury	Etiology			Range of LSCD			Follow-up in Months
			Male	Female				chronic cicatricial inflammation (SJS/OCP)	Others	Total	Partial			
Manyama-Hosoi F. 2005	R	85	38	40	52.5±19.5	17	43	25	85	0	85	0	46.6	
Shimazaki J. 2004	R	21	18	3	43.2±19.1	21	0	0	21	0	21	0	15	
Solomon A. 2002	R	39	21	10	40.1±14.6	16	11	12	39	0	39	0	34±21.5	
Ilari L. 2002	R	23	12	8	45	8	9	6	ND	ND	ND	ND	60	
Tsubota K. 1999	ND	43	26	13	49±23	29	14	0	ND	ND	ND	ND	38.7	
Tseng SC. 1998	R	7	4	3	54.3±17.6	2	3	2	ND	ND	ND	ND	11.3±4.6	
CLET (AM as the substrate)														
Parihar JK. 2017	P	25	14	11	46±6	15	6	4	20	5	20	5	12	
Cheng J. 2017	R	80	73	7	42.4±13.7	80	0	0	57	23	57	23	26.4±13.6	
Scholz SL. 2016	R	61	46	11	48.9±17.5	34	0	27	ND	ND	ND	ND	50.8±32.7	
Ramirez BE. 2015	P	20	12	8	51.6±14.2	7	4	9	12	8	12	8	36	
Ganger A. 2015	R	62	41	13	14.7±10	60	1	1	ND	ND	ND	ND	21.4±17.8	
Zakaria N. 2014	P	18	11	7	40.7±19.4	7	0	11	15	3	15	3	23.7±13.3	
Vazirani J. 2014	R	70	56	14	24±12.5	64	1	5	ND	ND	ND	ND	17.5±7	
Subramaniam SV. 2013	R	40	3	9	16.8±9.3	36	0	4	ND	ND	ND	ND	33.4±29.2	
Sejpal K. 2013	R	107	ND	ND	7.5±3.72	107	0	0	92	15	92	15	41.2±26	
Qi X.2013	R	42	ND	ND	38±14.7	42	0	0	42	0	42	0	17.8±3.8	
Prabhasawat P. 2012	P	19	12	7	44.7±15.2	13	1	5	11	8	11	8	26.1±13.5	
Basu S. 2012	R	50	35	15	20.7±11.4	50	0	0	50	0	50	0	27.6±16.8	
Basu S. 2012	R	28	17	3	27.9±17.4	18	3	7	28	0	28	0	58±33.6	
Sharma S, 2011	P	50	40	10	14.5±10	47	2	1	ND	ND	ND	ND	13.8±2.9	
Sangwan VS. 2011	R	200	159	41	24.1±9.9	200	0	0	200	0	200	0	36±19.2	
Pauklin M. 2010	P	44	27	11	47.4±20.1	22	0	22	32	12	32	12	28.5±14.9	
Meller D. 2010	R	30	22	6	47.4±20.1	16	0	14	18	12	18	12	28.9±15.5	
Shimazaki J. 2007	R	27	18	9	50.2±20.7	9	17	1	27	0	27	0	31.8	
Sangwan VS. 2006	R	88	74	12	21.1±12.5	78	0	10	61	27	61	27	18.3±11.2	
Schwab IR. 2000	P	14	11	3	49.4±14	6	1	7	ND	ND	ND	ND	11.5±6.6	
COMET (AM as the substrate)														
Prabhasawat P. 2016	P	20	7	11	48.2±15.5	7	10	3	15	5	15	5	31.9±12.1	

Author (Year)	Study Type	No. of Eyes	Gender		Mean Age	Chemical/Thermal Injury	Etiology			Range of LSCD			Follow-up in Months
			Male	Female			chronic cicatricial inflammation (SJS/OCP)	Others	Total	Partial			
Dobrowolski D. 2015	P	17	3	10	31.1±11.5	0	0	0	17	14	3	16±2.2	
Hirayama M. 2012	R	16	11	5	58.4±17.7	6	10	0	0	16	0	35±17.6	
Satake Y. 2011	R	40	22	14	58.5	11	21	8	8	40	0	25.5	
Nakamura T. 2011	R	19	7	10	54±21	1	15	3	3	19	0	55±17	
Inatomi T. 2006	R	15	9	6	48.4±22.3	6	8	1	1	15	0	20±11	
SLET													
Iyer G. 2017	R	18	8	9	ND	18	0	0	0	ND	ND	10.3±6.7	
Arora R. 2017	P	10	ND	ND	15.2±10.8	10	0	0	0	7	3	6	
Vazirani J. 2016	R	68	51	17	22	62	0	6	6	46	22	12	
Basu S. 2016	P	125	82	43	ND	125	0	0	0	107	18	18	

AM: amniotic membrane; AMT: amniotic membrane transplantation; CLAL: conjunctival limbal allograft transplantation; CLAU: conjunctival limbal autograft transplantation; CLET: cultivated limbal epithelial transplantation; COMET: cultivated oral mucosal epithelial transplantation; KLAL: keratolimbal allograft transplantation; ND: not documented; OCP: ocular cicatricial pemphigoid; P: prospective; R: retrospective; SLET: simple limbal epithelial transplantation; SJS: Stevens-Johnson Syndrome

Table 2

Comparisons on the outcome among CLAU/CLAL/KLAL with or without combined use of AMT

	AMT not used/mentioned	with AMT
<i>Reepithelization time (Days)</i>		
CLAU/CLAL	6.4-35.6 ^{46,59,83,88}	5.6-23.8 ^{15,46,59}
KLAL	8.4-12.7 ^{88,94}	
<i>Successful rate</i>		
CLAU		
1Y	75% ⁸³	43%-91% ^{65,67}
1.5Y	77%-81% ^{59,84,85}	67%-92% ^{15,59,78}
2Y		67% ⁸²
3Y	76% ⁸⁶	33% ⁶⁷
CLAL		
1Y	53%-70% ^{87,88}	38%-85% ^{15,66,70}
1.5Y	7.1%-40% ^{59,83,84}	67% ⁵⁹
2Y		33%-71% ^{15,62,66}
3Y	39%-59% ^{86,87}	23%-67% ^{67,70}
KLAL		
1Y	40%-83% ^{87,90,93,94}	33%-83% ^{49,65,72,76}
2Y	59%-86% ^{90,91}	33%-73% ^{72,77,89}
3Y	74% ⁹²	27%-54% ^{55,56,72,76}
4Y	58% ⁹⁰	33%-66% ^{63,71}
5Y	51% ⁹⁰	21%-47% ^{56,72}

AMT: amniotic membrane transplantation; CLAL: conjunctival limbal allograft transplantation; CLAU: conjunctival limbal autograft transplantation; KLAL: keratolimbal allograft transplantation; Y: year

Table 3

Comparisons on the outcome between AM and fibrin as the substrate in CLET and COMET

substrate	AM	Fibrin
<i>Reepithelization time (Day)</i>		
CLET	5-13.7 ^{138,144}	
COMET	5.2 ¹²⁷	
<i>Successful rate</i>		
CLET		
1Y	60%-91% ^{29,93,113,118-120,136,138,142-144}	62%-80% ^{102,103,158}
2Y	56%-81% ^{32,110,114,117-120,135-138,140,141}	
3Y	47%-75% ^{119,120,134,136,138}	77% ⁹⁹
4Y	45% ¹¹⁸	
5Y	64%-75% ^{136,139}	
8Y		66% ¹⁵⁹
COMET		
1Y		63%-88% (substrate free) ^{146,147}
	44%-65% ^{123,127,129,147}	
2Y	59%-79% ^{127,129}	64% (fibrin) ¹⁶⁰
3Y	53%-71% ^{126,129,145}	

AM: amniotic membrane; CLET: cultivated limbal epithelial transplantation; COMET: cultivated oral mucosal epithelial transplantation;